INTRODUCTION
============

Ca^2+^ signalling controls many cellular processes including cell growth, secretion and proliferation \[[@B1],[@B2]\]. Generation of Ca^2+^ signals in non-excitable cells involves rapid IP~3~ (inositol 1,4,5-trisphosphate)-dependent Ca^2+^ release from intracellular stores followed by external Ca^2+^ entry through SOCCs (store-operated Ca^2+^ channels) \[[@B3]--[@B5]\]. These coupled processes are regulated by two dynamic transmembrane proteins, the ER (endoplasmic reticulum) Ca^2+^ sensor protein STIM1 (stromal interaction molecule 1) \[[@B6]--[@B10]\] and the PM (plasma membrane) protein Orai1 \[[@B9],[@B11]\]. STIM1 is a Ca^2+^ sensor within the ER that oligomerizes to form aggregates or 'puncta' in ER--PM junctions upon store depletion \[[@B7],[@B12]\]. Oligomerized STIM1 then binds to PM Orai1 to activate Ca^2+^ influx \[[@B13],[@B14]\]. Mutational analysis of the STIM1-interacting domains revealed that the cytoplasmic C-terminus of STIM1 is necessary and sufficient for the activation of SOCC influx and its associated Ca^2+^ release-activated Ca^2+^ current (*I*~CRAC~) \[[@B15]\]. More recently, a minimal region has been identified within the C-terminus of STIM1, which is required to interact with and activate Orai1 clustering and SOCC influx \[[@B16]--[@B20]\].

A previous paper by Varnai et al. \[[@B21]\] suggested that STIM1 and Orai1 form part of a large macromolecular complex, which may indicate the presence of other proteins within STIM1--Orai1 clusters. One potential candidate for this is Golli protein, encoded by the *MBP* (myelin basic protein) gene; Golli proteins are alternative splice isoforms of the classic MBP proteins \[[@B22]\]. Unlike MBP, which is a major constituent of myelin in the nervous system, Golli proteins are expressed ubiquitously, although their function is not well understood. The BG21 isoform of Golli (Golli-BG21) is expressed at high levels in T-cells \[[@B23]\] where it acts as a negative regulator of T-cell activation \[[@B22]\]. T-cells from Golli-deficient mice are hyperproliferative and exhibit increased IL (interleukin)-2 production \[[@B24]\]. It has been shown that this is due to enhanced SOCC influx in Golli-deficient cells, suggesting that Golli is a negative regulator of SOCE (store-operated Ca^2+^ entry) \[[@B24]\]. Conversely, overexpression of Golli-BG21 in Jurkat T cells results in decreased SOCC influx \[[@B24]\]. Golli-BG21 also regulates voltage-gated Ca^2+^ channels and SOCCs to mediate the migration and proliferation of oligodendrocyte precursor cells \[[@B25]--[@B27]\]. Interestingly, a fraction of Golli-BG21 is constitutively localized to lipid rafts at the PM and this PM association increases following T-cell stimulation \[[@B24]\]. Mutation of the N-terminal Golli myristoylation site, required for PM association, abolishes its ability to regulate Ca^2+^ influx \[[@B24]\]. Golli-BG21 does not affect the IP~3~-dependent release of Ca^2+^ from internal stores, but rather regulates store-depletion-induced Ca^2+^ entry itself \[[@B24]\]. It is not yet known how Golli-BG21 regulates SOCC activity in T-cells, i.e. whether it is due to a direct effect on the channel itself or through the regulation of the signalling pathway responsible for SOCC activation. In the present study we show that Golli-BG21 interacts with the SOCC activator STIM1 and suggest that down-regulation of SOCE is the likely consequence of this interaction.

MATERIALS AND METHODS
=====================

Plasmid construction
--------------------

All expression vectors were purchased from Clontech, except pGEX-6-P1, which was from GE Healthcare. The Golli-BG21--GFP (green fluorescent protein) plasmid was a gift from Dr Celia Campagnoni (University of California, Los Angeles, School of Medicine, Los Angeles, CA, U.S.A.). For affinity chromatography and binding experiments, the C-terminal domain of STIM1 (STIM1-CT; amino acids Met^241^-- Lys^685^), the C- and N-terminal domains of Orai1 \[Orai-CT (amino acids Ala^267^--Ala^315^) and Orai-NT (amino acids Met^1^--Leu^86^)\] and the full-length Golli-BG21 protein were subcloned into the pGEX-6-P1 vector using BamHI/SacII for STIM1-CT, and BamHI/XhoI for Golli and Orai1. For split YFP (yellow fluorescent protein) experiments, STIM1-CT and Golli-BG21 were subcloned into YFP-YN (N-terminal half of YFP) and YFP-YC (C-terminal half of YFP) vectors respectively \[[@B28]\]. STIM1-CT was subcloned into pEYFP-N1 and YFP-YN using HindIII/SacII and Golli-BG21 was subcloned into pmCherry-N1 (a gift from Dr Roger Y. Tsien, Department of Pharmacology, University of California, San Diego, CA, U.S.A.) and YFP-YC using XhoI/SacII for co-localization experiments. Construction of STIM1--EYFP (enhanced YFP) and mCherry--Orai1 has been described previously \[[@B29]\], as has construction of pmCherry--Rit1 \[[@B30]\].

Affinity chromatography and MALDI--TOF (matrix-assisted laser-desorption ionization--time-of-flight) MS
-------------------------------------------------------------------------------------------------------

Extracts of bovine brain were prepared as described previously \[[@B31]\]. GST (glutathione transferase) fusion proteins were expressed in *Escherichia coli*, immobilized on to glutathione--cellulose beads (Bioline) and incubated with 1 ml of extracted cytosolic bovine brain proteins on a rotator for 2 h at 4 °C. The beads were washed with wash buffer \[25 mM Tris/HCl, pH 7.8, 50 mM KCl and 1 mM DTT (dithiothreitol)\] and proteins eluted by boiling in Laemmli buffer. Eluted proteins were purified by methanol precipitation, denatured by boiling in SDS buffer, and analysed by SDS/PAGE. Protein bands of interest were excised and subjected to in-gel tryptic digestion and MALDI--TOF MS as described previously \[[@B32]\].

Binding assays
--------------

GST control or GST--Golli fusion proteins were immobilized on to glutathione--cellulose beads and incubated with 2 μM STIM1-CT protein, which had been treated with the PreScission protease (GE Healthcare) to cleave the GST tag. Samples were eluted by boiling in Laemmli buffer and analysed by Western blotting using an anti-STIM1 antibody (1:1000 dilution; ProSci) and a HRP (horseradish peroxidase)-linked anti-(rabbit Ig) secondary antibody.

Cell culture and transfection
-----------------------------

HeLa cells were maintained as described previously \[[@B29]\]. Cells were transfected with 1 μg of the plasmid(s) of interest using GeneJuice (Merck Biosciences) and cultured for 24 h.

BiFC (bimolecular fluorescence complementation) assays and co-localization studies
----------------------------------------------------------------------------------

For BiFC assays, HeLa cells were transfected with Golli-BG21--YC and STIM1-CT--YN constructs either alone or together. For further control experiments, HeLa cells were transfected with the empty BiFC vectors (YFP-YC and YFP-YN), Golli-BG21--YC and YFP-YN, or STIM1-CT--YN and YFP-YC. Cells were treated with 2 μM thapsigargin at room temperature (23 °C) for 90 min before imaging. For co-localization studies, HeLa cells were co-transfected with mCherry--Orai1 together with Golli-BG21--YC/STIM1-CT--YN or STIM1-CT--YFP, STIM1--EYFP and mCherry--Golli, or triply transfected with STIM1--EYFP, mCherry--Orai1 and Golli-BG21--GFP and imaged 24 h post-transfection.

Ca^2+^ measurements
-------------------

Cells grown on glass-bottomed dishes were placed in standard buffer (10 mM Hepes, pH 7.3, containing 140 mM NaCl 4.7 mM KCl, 2 mM CaCl~2~, 1.13 mM MgCl~2~ and 10 mM glucose) and loaded with 5 μM Fluo 4 AM (Fluo 4 acetoxymethyl ester) for 30 min at room temperature before washing in Ca^2+^-free standard buffer. Ca^2+^ imaging was carried out using a Leica AOBS SP2 microscope. HeLa cells expressing STIM1--EYFP, Golli--mCherry or a combination of both were pretreated with 2 μM thapsigargin (Calbiochem) in the absence of extracellular Ca^2+^ for 10 min to deplete stores; 2 mM Ca^2+^ was then added to activate SOCE \[[@B30]\].

Quantification of STIM1 puncta
------------------------------

Quantification of STIM1--EYFP puncta was performed as described previously \[[@B30]\]. Briefly, puncta were selected as spots of high fluorescence intensity ranging from approx. 0.5--1.0 μm in diameter. Accuracy of puncta quantification was verified by independent blind counting.

Quantification of Golli--mCherry fluorescence
---------------------------------------------

To determine the extent of Golli--mCherry fluorescence in cells overexpressing STIM1--EYFP compared with cells that do not overexpress STIM1, regions of interest were drawn around the outside of each cell. Fluorescence values were calculated on the basis of the mean fluorescence per pixel within the cell rather than total fluorescence to avoid problems arising from variations in the size of the selected regions of interest.

RESULTS
=======

To search for novel binding partners for STIM1 and Orai1, we performed pull-down experiments on immobilized cytosolic domains of the STIM1 and Orai1 GST-fusion proteins \[GST--STIM-CT (\~80 kDa), GST--Orai1-CT (\~34.5 kDa) and GST--Orai1-NT (\~33 kDa)\] using bovine brain cytosol ([Figure 1](#F1){ref-type="fig"}A). MALDI--TOF MS analysis of unique protein bands from the pull-down identified MBP (eight matching peptides with 39% sequence coverage), as a protein of approx. 25 kDa in size, which bound to the C-terminus of STIM1. Western blotting using an anti-MBP antibody confirmed that MBP bound specifically and efficiently to STIM1 and also bound to the N-terminus of Orai1 ([Figure 1](#F1){ref-type="fig"}B). Note that a similar sized polypeptide was present in the control GST pull-down sample ([Figure 1](#F1){ref-type="fig"}A). The identity of this polypeptide was not established, but it was not recognized by the anti-MBP antibody ([Figure 1](#F1){ref-type="fig"}B). The finding of MBP binding was surprising, since classic MBP itself is required for central nervous system myelination and has not been implicated in the activity of SOCCs. The Golli family of proteins are alternatively spliced variants of classical MBPs, which have been shown to mediate signal transduction in T-cells through the negative regulation of SOCCs \[[@B24]\]. As Golli proteins contain MBP epitopes, we hypothesized that Golli may interact with STIM1 to exert its effect on SOCE. We assessed whether the C-terminus of STIM1 interacts directly with Golli using an *in vitro* binding assay. A recombinant GST--Golli-BG21 fusion protein (\~57.5 kDa) was expressed in *E*. *coli* and immobilized on to a glutathione affinity resin. Immobilized GST--Golli-BG21 or GST control protein (\~26 kDa) was incubated with PreScission-cleaved STIM1CT (\~54 kDa). Western blotting analysis revealed that STIM1-CT bound specifically to the GST--Golli-BG21 protein, but not to the GST control ([Figure 1](#F1){ref-type="fig"}C), confirming that the C-terminus of STIM1 does indeed interact with Golli *in vitro*. Note that in these experiments the glutathione beads were incubated with levels of GST or GST--Golli-BG21 that resulted in a 1.4-fold higher level of GST so that lack of binding of STIM1-CT to GST-loaded beads was not a consequence of the relative GST concentration. In similar experiments binding of Orai-NT to GST--Golli-BG21 could not be detected (results not shown).

![Golli binds to the C-terminus of STIM1\
(**A**) Coomassie-Blue-stained gel of eluates from GST, GST--Orai1-CT, GST--Orai1-NT and GST--STIM1-CT pull-down assays. GST columns were run in parallel with GST--Orai1-CT, GST--Orai1-NT and GST--STIM1-CT and incubated with bovine brain cytosol extract. Samples were eluted by boiling in Laemmli buffer. Eluted proteins were separated by SDS/PAGE. Subsequently, proteins were excised from gels and analysed by MALDI--TOF MS. MBP (arrow) was identified as a GST--STIM1-CT binding partner. (**B**) Western blotting analysis of eluates from GST, GST--Orai1-CT, GST--Orai1-NT and GST--STIM1-CT pull-down assays. Membranes were immunoblotted (IB) with anti-MBP antibody. (**C**) Purified STIM1-CT binding to GST--Golli. GST--Golli and GST--STIM1-CT fusion proteins were purified using glutathione--cellulose beads. GST--STIM1-CT was cleaved with PreScission protease to remove the GST tag. Glutathione--cellulose beads containing equal amounts of GST or GST--Golli were incubated with 2 μM STIM1-CT. Proteins were eluted in wash buffer containing 1 mM NaCl, methanol precipitated and boiled in Laemmli buffer. Samples were separated by SDS/PAGE and analysed by Western blotting with anti-STIM1 antibody. The molecular mass in kDa is indicated on the left-hand side of the gels.](bic516i001){#F1}

To investigate further the possible interaction of STIM1 and Golli-BG21 in a cellular context, we expressed these two proteins in HeLa cells using a BiFC assay \[[@B33]\]. This BiFC system involved the fusion of the complementary fragments of EYFP (i.e. YN and YC) to two proteins of interest. If these proteins interact the EYFP fragments come close enough to fold and form a functional fluorescent EYFP protein \[[@B28]\]. In these experiments, YC and YN were fused to the C-termini of the STIM1-CT (STIM1-CT--YN) and Golli (Golli-BG21--YC) proteins and expressed in HeLa cells along with a mCherry-tagged Rit1 (Ras-like without CAAX 1) tail protein (mCherry--Rit1), described previously \[[@B30]\], as a marker to identify transfected cells. No detectable fluorescence was observed in untreated cells ([Figure 2](#F2){ref-type="fig"}A). Transfected cells were treated with thapsigargin for 60--90 min at room temperature in 2 mM external Ca^2+^ before imaging with a confocal microscope. EYFP fluorescence was detected at the PM in treated cells expressing STIM1-CT--YN and Golli-BG21--YC at approx. 90 min following the addition of thapsigargin ([Figure 2](#F2){ref-type="fig"}B), which is consistent with the time course described for the refolding of EYFP at room temperature \[[@B33]\]. EYFP fluorescence was distributed throughout the PM, but no puncta were visible. The uniform PM EYFP fluorescence observed was consistent with the previous finding that although STIM1-CT expression gives constitutive activation of the *I*~CRAC~, it does not form puncta at the PM \[[@B34]\] as it requires an ER localization to oligomerize prior to translocation to ER--PM junctions \[[@B34],[@B35]\]. We also observed that STIM1-CT--EYFP co-localizes with the mCherry--Orai1 protein at the PM in HeLa cells, but does not form visible puncta (results not shown). No detectable EYFP fluorescence was observed in thapsigargin-treated cells expressing either the STIM1--YN or Golli-BG21--YC fusion protein alone ([Figures 2](#F2){ref-type="fig"}C and [2](#F2){ref-type="fig"}D) or along with the appropriate complementary fragment of YFP ([Figures 2](#F2){ref-type="fig"}E and [2](#F2){ref-type="fig"}F). Similarly, co-expression of both EYFP fragments failed to produce a fluorescent signal and served as a negative control ([Figure 2](#F2){ref-type="fig"}G). There are two possibilities to explain why EYFP fluorescence was observed at the PM only following thapsigargin treatment. First, STIM1-CT--YN may associate with endogenous STIM1 puncta enabling it to interact with Golli-BG21--YC at the PM. Secondly, it is also possible that a change in cytosolic Ca^2+^ concentration may be required to modulate an interaction between STIM1-CT--YN and Golli-BG21--YC. To investigate this, HeLa cells expressing both constructs were treated with 100 μM histamine, which should induce transient oscillations in cytoplasmic Ca^2+^, in place of thapsigargin. Plasmalemmal EYFP fluorescence formation was observed ([Figure 2](#F2){ref-type="fig"}H) even though full-length STIM1--EYFP did not reveal substantial sustained puncta formation under these conditions (results not shown) suggesting that an increase in cytosolic Ca^2+^ from intracellular stores modulates the interaction between STIM1-CT and Golli-BG21. PM EYFP fluorescence was also observed in cells that were not co-transfected with mCherry--Rit1 (results not shown), eliminating the possibility that the transfection marker was targeting the BiFC constructs to the PM. The emission spectrum for the fluorescence observed with STIM1--YN/Golli-BG21--YC was close to that of EYFP ([Figure 2](#F2){ref-type="fig"}I), confirming that the fluorescence observed was due to formation of functional EYFP. The BiFC assay was also used to determine whether Golli interacts with full-length STIM1--YN or Orai1--YN. However, EYFP fluorescence was not observed in cells transfected with Golli--YC and Orai1--YN or full-length STIM1--YN that had been treated with thapsigargin for 90 min (results not shown).

![STIM1-CT--YN and Golli-BG21--YC fusion proteins reconstitute EYFP fluorescence at the PM\
HeLa cells were co-transfected with mCherry--Rit1 as a transfection marker (right-hand panels). At 24 h post-transfection, cells were treated with 2 μM thapsigargin (Thapsi) for 90 min and imaged using a confocal microscope, except in (**A**) where cells were imaged without treatment. (**A**) Co-expression of Golli--YC/STIM1-CT--YN in untreated cells does not result in the formation of EYFP (*n*=21 cells). (**B**) Co-expression of Golli--YC/STIM1-CT--YN results in reconstitution of EYFP fluorescence at the PM when cells were treated with thapsigargin (*n*=35 cells). (**C**) Expression of Golli--YC (*n*=12 cells) alone, (**D**) STIM1-CT--YN (*n*=20 cells) alone, (**E**) STIM1-CT--YN with YC (*n*=27 cells) or (**F**) Golli--YC with YN (*n*=18 cells) fails to restore EYFP fluorescence in thapsigargin-treated cells. (**G**) Similarly, co-expression of the YC and YN proteins gives no EYFP fluorescence following thapsigargin treatment. (**H**) Treatment of cells with 100 μM histamine in place of thapsigargin also reconstitutes EYFP fluorescence (*n*=27 cells). EYFP fluorescence from (**B**) was recorded using the Lambda scan mode. Fluorescence intensity, after 453 nm excitation, was recorded in 5 nm intervals from 510 nm to 590 nm; the emission spectrum was similar to that of EYFP (**I**). Scale bars=10 μm; a. u., arbituary units.](bic516i002){#F2}

Interestingly, when mCherry-Orai1 was co-expressed with STIM1-CT--YN/Golli-BG21--YC in HeLa cells, the EYFP fluorescence clearly overlapped with the mCherry--Orai1 signal ([Figure 3](#F3){ref-type="fig"}A). Furthermore, a Golli-BG21--GFP fusion co-localized with both mCherry--Orai1 and STIM1-CT--EYFP in HeLa cells ([Figure 3](#F3){ref-type="fig"}B and insert). This led us to examine whether Golli co-localizes with full-length STIM1 and Orai1 in puncta, thereby placing the protein in a position to regulate the activity of these proteins. Golli overexpression has been shown to decrease SOCE following store depletion in Jurkat T cells \[[@B24]\]. If this occurred through an interaction with STIM1, the Golli protein would either co-localize with STIM1 in puncta or would prevent STIM1 puncta formation. To test this, full-length STIM1--EYFP and a Golli-BG21--mCherry fusion protein were expressed in HeLa cells. No co-localization between STIM1--EYFP and Golli-BG21--mCherry was observed in untreated HeLa cells, where STIM1--EYFP expression was reticular and Golli-BG21--mCherry was distributed throughout the PM as observed previously \[[@B24]\] ([Figure 3](#F3){ref-type="fig"}C). However, when cells were treated with thapsigargin for 10 min before imaging to induce STIM1 puncta formation, Golli--mCherry expression was observed predominantly at the PM where STIM1--EYFP puncta accumulated, but was also seen to co-localize with STIM1--EYFP in a subset of puncta ([Figure 3](#F3){ref-type="fig"}D and insert). We also examined whether Golli--GFP co-localized with punctate STIM1--EYFP and mCherry--Orai1 complexes in HeLa cells after thapsigargin treatment. Indeed it appeared that all three proteins co-localized to the same punctate structures ([Figure 3](#F3){ref-type="fig"}E and insert). We did not see any change in the number of STIM1--EYFP puncta formed in thapsigargin-treated cells overexpressing Golli--mCherry compared with control cells expressing STIM1--EYFP alone ([Figure 3](#F3){ref-type="fig"}F) suggesting that Golli does not affect the formation of STIM1 puncta itself. The targeting of both proteins to the same punctate structures suggests that Golli and full-length STIM1 interact and that Golli may regulate SOCE through a direct interaction with STIM1 in puncta.

![STIM1, Orai1 and Golli co-localize in HeLa cells\
(**A**) HeLa cells were co-transfected with STIM1-CT--YN/Golli-YC and mCherry--Orai1. At 24 h post-transfection, cells were treated with 2 μM thapsigargin for 90 min and imaged using a confocal microscope. Reconstituted EYFP fluorescence from STIM1-CT--YN/Golli--YC co-localizes with mCherry--Orai1. (**B**) STIM1-CT--EYFP, mCherry--Orai1 and Golli-BG21--GFP show co-localization in HeLa cells (the enlarged insert is taken from the top left of the cell). (**C**) Full-length STIM1--EYFP does not co-localize with Golli-BG21--mCherry in untreated cells. (**D**) STIM1--EYFP puncta show co-localization with Golli-BG21--mCherry in thapsigargin-treated HeLa cells (the enlarged insert is taken from the top of the cell). (**E**) Full-length STIM1--EYFP, mCherry--Orai1 and Golli-BG21--GFP show co-localization in puncta following thapsigargin treatment in HeLa cells (the enlarged insert is taken from the middle left side of cell). (**F**) Cells expressing STIM1--EYFP alone (*n*=43) or in combination with Golli-BG21--mCherry (*n*=19) were analysed and the number of puncta formed following thapsigargin treatment counted and expressed as the mean number per cell (±S.E.M.). There was no significant difference in the number of STIM1 puncta formed in the presence or absence of Golli-BG21--mCherry. Scale bars=10 μm.](bic516i003){#F3}

To determine whether Golli affects SOCE in HeLa cells, we transfected cells with Golli--mCherry or STIM1--EYFP alone or in combination and loaded cells with the cytosolic Ca^2+^ indicator, Fluo 4 AM. Stores were depleted with thapsigargin in Ca^2+^-free medium for approx. 10 min and Ca^2+^ influx was measured upon re-addition of Ca^2+^ to the external solution. Untransfected cells in the same field of view as transfected cells were used as internal controls. Golli-expressing cells exhibited a reduced rate and extent of Ca^2+^ influx compared with influx in untransfected control cells ([Figure 4](#F4){ref-type="fig"}A), which was statistically significant (*P*\<0.0001) at the 750 s time point. This is consistent with previous findings that Golli-deficient T-cells show enhanced SOCE and that overexpression of Golli-BG21 inhibits SOCE \[[@B24]\], and suggests that Golli negatively regulates SOCE. In STIM1-overexpressing cells there was an increase in the initial rate of SOCE when compared with untransfected cells ([Figure 4](#F4){ref-type="fig"}A), which we have observed previously \[[@B30]\]. Interestingly, overexpression of STIM1 abolished the inhibitory effect of Golli-BG21 when compared with STIM1-overexpressing cells ([Figure 4](#F4){ref-type="fig"}A). This was not due to differences in the expression of Golli as the level of Golli-BG21--mCherry fluorescence was similar in cells expressing Golli-BG21--mCherry alone or in combination with STIM1--EYFP ([Figure 4](#F4){ref-type="fig"}B). It is therefore possible that high levels of STIM1 protein expression can directly overcome the inhibition of SOCE by Golli-BG21.

![Overexpression of Golli reduces store-operated Ca^2+^ influx, but this is reversed by overexpression of STIM1\
(**A**) HeLa cells were transfected with Golli-BG21--mCherry and/or STIM1--EYFP. At 24 h post-transfection, cells were loaded with 5 μM Fluo 4 at room temperature for 30 min. Cells were treated with 2 μM thapsigargin to deplete the stores, followed by the readdition of 2 mM Ca^2+^ to the external solution. Changes in \[Ca^2+^\]~i~ were measured and compared in transfected and untransfected cells. The results are means±S.E.M. For untransfected cells, *n*=154 cells; for Golli-BG21--mCherry-transfected cells, *n*=63 cells; for STIM1--EYFP transfected cells, *n*=36 cells; for Golli-BG21--mCherry- and STIM1--EYFP-transfected cells, *n*=55 cells. (**B**) Golli-BG21--mCherry fluorescence was quantified in cells expressing Golli-BG21--mCherry alone (*n*=175) or together with STIM1--EYFP (*n*=128). Expression levels of Golli-BG21--mCherry were similar in both conditions.](bic516i004){#F4}

DISCUSSION
==========

Previous studies identified Golli-BG21 as a regulator of SOCE. This has been particularly well established for T-cells where knockout of Golli increased SOCE and overexpression of Golli-BG21 decreased SOCE \[[@B24]\]. It was not clear, however, from these studies whether Golli has a direct effect on the SOCC itself or another protein or pathway involved in the activation of SOCE. In the present study, we suggest that Golli directly interacts with the master SOCE regulator STIM1 to reduce SOCE. The C-terminal domain of STIM1 successfully bound to Golli in GST-binding assays and BiFC assays. We have not mapped the STIM1-interacting domain within Golli, but it is possible that this is an epitope that is shared with the classical MBP protein given the C-terminus of STIM1 binds to MBP from bovine brain extract in pull-down assays. We have shown in the present study, using a BiFC assay, that the interaction between Golli-BG21 and the C-terminus of STIM1 can be detected in cells after stimulation by both thapsigargin and histamine treatment. Both of these compounds should produce changes in cytosolic Ca^2+^ levels but, unlike thapsigargin, histamine elicits transient Ca^2+^ oscillations in HeLa cells \[[@B36],[@B37]\]. As the formation of STIM1--EYFP puncta was not observed under conditions where histamine stimulated BiFC fluorescence between STIM1--YN and Golli--YC, it is possible that it is the modulation of the cytosolic Ca^2+^ concentration by both thapsigargin and histamine rather than sustained translocation of endogenous STIM1 that induces an interaction between the C-terminus of STIM1 and Golli-BG21. The BiFC assay was used in the present study since it is a more robust method for investigating protein interactions in live cells than other techniques such as FRET (fluorescence resonance energy transfer). It is important to note, however, that the BiFC assay is not reflective of the kinetics of the interaction, since binding between the YC and YN fragments of EYFP is essentially irreversible and refolding of the full EYFP protein and the reconstitution of fluorescence requires some time \[[@B33]\], in this case, up to 90 min. Irrespective of the lack of information from these experiments on the kinetics of the STIM1--Golli-BG21 interaction, this assay provides the most convincing evidence of a direct protein--protein interaction in living cells.

No fluorescence complementation was observed in cells expressing Golli--YC and Orai1--YN, or Golli--YC and full-length STIM1--YN (results not shown). EYFP fluorescence was also absent in cells expressing Orai1--YC and STIM1-CT--YN (results not shown), even though the STIM1 and Orai1 proteins are known to interact \[[@B16],[@B34],[@B38]\]. There are several reasons why this may have occurred. First, fusion of an EYFP fragment to a protein may alter the structure of the protein, thereby abolishing an interaction domain within the protein of interest \[[@B39]\]. Secondly, the arrangement of the BiFC fusion proteins within a protein complex may sterically hinder an interaction between the complementary EYFP fragments and prevent the formation of functional EYFP \[[@B39]\]. The lack of EYFP fluorescence between Golli--YC and Orai1--YN, and Golli--YC and full-length STIM1-YN proteins is therefore not conclusive evidence for the absence of an interaction between these protein pairs. We also could not confirm the potential interaction of Orai-NT to GST--Golli-BG21, seen in the initial GST pull-down from brain extract, in a direct binding assay with recombinant proteins.

Despite the large amount of recent research into the activation of SOCCs, very few interacting partners have been found for STIM1 and Orai1. One recent study has identified a novel EF-hand-containing protein CRACR2A (CRAC regulator 2A), which binds to both STIM1 and Orai1 to stabilize their interaction, thereby enhancing SOCE in T-cells \[[@B40]\]. Additionally, little is known about the Ca^2+^-dependent inactivation of these channels. One recent study reported that both calmodulin and a short negatively charged region within the STIM1 C-terminus can bind to Orai1 to inactivate SOCE \[[@B41]\]. Interestingly, in the present study, Golli-BG21 co-localized with STIM1 and Orai1 complexes after store depletion. The ability of Golli-BG21 to bind STIM1 puncta in a Ca^2+^-dependent manner may be key to its regulation of SOCE. It is possible that Golli-BG21 binds to STIM1--Orai1 complexes when Ca^2+^ levels are already high to reduce the influx of Ca^2+^ into the cell and perhaps may be a further contributor to the Ca^2+^-dependent inactivation of SOCCs. When STIM1 was overexpressed with Golli-BG21, the inhibitory effect of Golli-BG21 on SOCE was abolished. This was not due to variation in the expression levels of Golli-BG21 achieved in the presence and absence of STIM1, suggesting that an interaction between STIM1 and Golli-BG21 overcomes the ability of Golli to reduce SOCE.

To date, studies on MBP and Golli, and their regulation of Ca^2+^ channels, have focussed exclusively on oligodendrocyte precursor cells and T-cells. Of the three Golli isoforms cloned, the BG21 isoform of Golli is the most widely expressed in many different tissues, other than nervous tissues, including the heart, kidney, spleen and lung \[[@B23]\], although its function in these tissues has not been elucidated. The widespread distribution of Golli-BG21 suggests that it could be part of a general mechanism for the regulation of SOCE across many tissue types. Hence, we propose that Golli-BG21 functions to regulate SOCE via a direct interaction with STIM1, but the exact molecular mechanism underlying this interaction has yet to be defined.
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